Nuvation Bio Investor Presentation November 2023

Nuvation Bio presents its oncology-focused pipeline of wholly-owned drug candidates, including the BET inhibitor NUV-868 in Phase 1 trials and a Drug-Drug Conjugate platform with an IND filing planned by year-end 2023. The presentation outlines the company's clinical development progress across multiple solid tumor indications with combination therapy approaches.